Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leukotuximab - DiNonA

Drug Profile

Leukotuximab - DiNonA

Alternative Names: Anti-JL1 monoclonal antibody; ART-140; DNP-001; EGX-040; EGX-140; SSS-19

Latest Information Update: 28 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Seoul
  • Developer 3SBio; Arana Therapeutics; Asan Medical Center; DiNonA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action JL1 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 28 Jun 2020 No recent reports of development identified for preclinical development in Leukaemia in China (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Leukaemia and Myelodysplastic syndromes (Second-line therapy or greater, In adults, In the elderly) in South Korea (IV)
  • 12 May 2016 Preclinical trials in Leukaemia in China (Parenteral)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top